USA flag logo/image

An Official Website of the United States Government

Controlled Release Bone Morphogenic Protein/Nano-calcium

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76136
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
DE017468
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Spire Corporation
One Patriots Park Bedford, MA 01730-2396
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Controlled Release Bone Morphogenic Protein/Nano-calcium
Agency: HHS
Contract: 1R43DE017468-01
Award Amount: $156,878.00
 

Abstract:

DESCRIPTION (provided by applicant): Controlled Release of Bone Morphogenic Protein using Nano-Calcium Phosphate Coatings TP-2004-71 We propose a novel method for depositing a drug-loaded coating based on a mixture of nano-phase calcium phosphate and bone morphogenic protein (BMP) on metal implants. One unique feature of the coating is that it will release the drug in a controlled fashion following the surgical procedure. Additionally, the coating is made up of nano-sized calcium phosphate features, which we have shown in preliminary studies to significantly enhance osteoblast function. In Phase I feasibility studies, three nano-calcium phosphate coating formulations (amorphous, semi- crystalline and crystalline) will be synthesized at Purdue University. Nano-phase calcium phosphate will then be mixed with BMP and coated onto titanium substrates using our novel deposition process. The coating on these samples will be evaluated for rate of release with the goal of reproducing our successful previous results from pelletized form of nano-CaPCVBMP material. After controlled rate of release has been demonstrated, we will assess protein bioactivity in vitro using osteoblast reactivity assay on nano-calcium phosphate material with and without BMP. Various structural and material characteristics of the coated samples will be studied using SEM, XRD, AFM and EDS. In Phase II, nano-CaPCVBMP coatings on implants will be evaluated in an in vivo animal model.

Principal Investigator:

Marisa A. Sambito
7812756000
MSAMBITO@SPIRECORP.COM

Business Contact:

Mark Little
7812756000
MLITTLE@SPIRECORP.COM
Small Business Information at Submission:

Spire Corporation
Spire Corporation 1 Patriots Park Bedford, MA 01730

EIN/Tax ID: 042457335
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No